Health Canada has approved the first drug designed to treat postpartum depression.

Zuranolone, sold under the brand name Zurzuvae, is a pill taken once a day for 14 days and can start relieving depressive symptoms in as few as three days.

Manufactured by Biogen, the drug has been approved for use in the United States since late 2023 and is also authorized in the U.K. and the European Union.

According to Health Canada’s website, one in five women experience a depression or anxiety disorder during or after pregnancy.